Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04365153 · ClinicalTrials.gov registry record · Phase 2
Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
A Phase 2 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT04365153 is a Phase 2 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 45 participants.
The verdict
NCT04365153, a Phase 2 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in patients with COVID-19 infection. These results will lead to and inform a Phase III randomized placebo-controlled trial.
Interventions
- DRUG Placebos
- DRUG Canakinumab Injection 600mg
- DRUG Canakinumab Injection 300mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04365153
The ClinicalTrials.gov registry entry for NCT04365153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.
NCT04365153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04365153 about?
NCT04365153 is a clinical study titled "Canakinumab in Covid-19 Cardiac Injury (The Three C Study)". TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in patients with COVID-19 infection. These results will lead to and inform a...
What is the current status of trial NCT04365153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-04-24. Estimated completion is 2021-04-01.
What interventions are being tested in trial NCT04365153?
The interventions under investigation include: Placebos (DRUG), Canakinumab Injection 600mg (DRUG), Canakinumab Injection 300mg (DRUG).
Who is sponsoring clinical trial NCT04365153?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.